Business
Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stoc
About this update from Scilex Holding Company
[{"type":"image","alt":"Scilex Holding Company","displaySize":"","headline":null,"caption":"Scilex Holding Company","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/9b2e3809b02a2a884909cf9194da8b1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BaZBI9MyaHmZ0IuVZrA_gg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9b2e3809b02a2a884909cf9194da8b1d","width":300,"height":85}},"lazy":false},{"type":"text","content":"PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”) at a reduced exercise price of $22.51 per share. The aggregate gross proceeds from the exercise of the Existing Warrants were approximately $20.3 million, before deducting placement agent fees and other offering expenses payable by the Company.","length":1037,"tagName":"p"},{"type":"text","content":"Rodman & Renshaw LLC and StockBlock Securities LLC acted as the exclusive placement agents for the offering (the “Offering”).","length":129,"tagName":"p"},{"type":"text","content":"In consideration for the immediate exercise of the Existing Warrants for cash, the Company issued to the holder of the Existing Warrants a new unregistered warrant to purchase up to an aggregate of 1,356,594 shares of Common Stock at an exercise price of $29.00 per share (the “New Warrant”). The New Warrant is exercisable immediately upon issuance and has a term of five years from the date of issuance.","length":405,"tagName":"p"},{"type":"text","content":"The Company expects to use the net proceeds from the Offering for working capital and general co...